Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropinirole PR Dose-Response in Advanced Parkinson's Disease
NCT01494532Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 4, randomised, double-blind trial of ropinirole in Parkinson's disease (PD) (6 arms), sponsored by GSK. Primary endpoint: Change From Baseline in Total Awake Time Spent 'Off' at Week 17. Started Apr 2012; status: completed.
02
Drugs
ropinirole
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT01494532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01494532.